ArgenX rises after 'best case scenario' FDA Vygart approval

argenx SE

11/04/2025 08:59

** Shares in ArgenX ARGX.BR are up 3.7% after the Belgian biotech company received FDA approval for syringe version of its Vyvgart drug, meeting the "best case scenario" modelled by Degroof Petercam

** The pre-filled syringe (PFS) will be self-admin permitted with no specific training nor monitoring required

** "This achievement is expected to get more new patients on drug and help ArgenX achieve its 2030 vision with 50k patients on drug," Degroof Petercam says

** "We see the approval as the next phase in maintaining Vyvgart's launch momentum," KBC analysts say

** Both brokers see around 4% price increase for PFS, which KBC says "should facilitate smooth access under Medicare Part D"

** Up to the previous session's close, the shares were down 18.6%​ YTD​

 (Reporting by Dimitri Rhodes)

 ((Dimitri.rhodes@thomsonreuters.com))